---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000084"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:44:59.417293+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "low"
source: SEC EDGAR
---

# Caribou announces positive long-term follow-up for CB-010 in ANTLER Phase 1

## Summary
- Positive long-term follow-up results from dose escalation of ANTLER Phase 1 for CB-010 in relapsed/refractory B-NHL.
- CB-010 is an allogeneic anti-CD19 CAR-T cell therapy; study remains ongoing.
- Detailed clinical data summary filed as Exhibit 99.1; specific results not provided in the filing excerpt.
- Announcement made on July 13, 2023; no financial or regulatory guidance changes.

## SEC filing metadata
- accession: 0001619856-23-000084
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000084/0001619856-23-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000084/crbu-20230713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000084
- JSON: https://secwatch.observer/filing/0001619856-23-000084.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.